Stockscreener 앱 받기
10.84
4.69%
0.485
시장 영업 전:
10.83
-0.005
-0.05%
Biodesix Inc 주식(BDSX)의 최신 뉴스
Short Interest in Biodesix, Inc. (NASDAQ:BDSX) Declines By 48.4% - MarketBeat
Biodesix, Inc. Announces Fourth Quarter and Full Year 2025 Financial Results Release Date and Conference Call Details - Quiver Quantitative
Biodesix to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 - The Manila Times
Biodesix (NASDAQ:BDSX) CEO Scott Hutton Sells 3,559 Shares - MarketBeat
What is Biodesix Inc. s 5 year growth outlookQuarterly Investment Review & AI Based Buy and Sell Signals - mfd.ru
Biodesix, Inc. (NASDAQ:BDSX) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Biodesix, Inc. (NASDAQ:BDSX) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Can Biodesix Sustain Its Growth Momentum In 2026? - RTTNews
Telemark Asset Management, LLC Increases Stake in Biodesix Inc - GuruFocus
What is the dividend yield of Biodesix IncWeekly Investment Report & AI Forecast for Swing Trade Picks - baoquankhu1.vn
Biodesix (NASDAQ:BDSX) Director Jack Schuler Purchases 82,465 Shares - Defense World
Short Interest in Biodesix, Inc. (NASDAQ:BDSX) Increases By 499.1% - MarketBeat
Hedge Fund and Insider Trading News: Seth Klarman, Dan Loeb, Michael Burry, Michael Platt, Bridgewater Associates, Greenlight Capital, Biodesix Inc (BDSX), UWM Holdings Corp (UWMC), and More - Insider Monkey
Biodesix (NASDAQ:BDSX) Director Jack Schuler Purchases 80,000 Shares - MarketBeat
Biodesix (NASDAQ:BDSX) Director Acquires $236,000.00 in Stock - MarketBeat
Biodesix director Schuler buys $1.1m+ in BDSX stock By Investing.com - Investing.com South Africa
Biodesix director Schuler buys $1.1m+ in BDSX stock - Investing.com
Biodesix (NASDAQ:BDSX) Director Jack Schuler Buys 82,465 Shares - MarketBeat
Biodesix (BDSX) emeritus director Schuler buys $903k in stock By Investing.com - Investing.com Nigeria
Biodesix (BDSX) emeritus director Schuler buys $903k in stock - Investing.com
Perkins Capital Management Inc. Has $397,000 Position in Biodesix, Inc. $BDSX - MarketBeat
Big Money Moves: Can Biodesix Inc expand into new marketsTrade Risk Summary & Entry Point Confirmation Signals - baoquankhu1.vn
Reviewing Biodesix (NASDAQ:BDSX) and HealthEquity (NASDAQ:HQY) - Defense World
How geopolitical tensions affect Biodesix Inc. stockWeekly Trade Review & High Accuracy Investment Entry Signals - bollywoodhelpline.com
BDSX stock shot up 23% pre-market today — what’s fueling the surge? - MSN
Biodesix Inc. (BDSX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Biodesix, Inc. (NASDAQ:BDSX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Investors Still Aren't Entirely Convinced By Biodesix, Inc.'s (NASDAQ:BDSX) Revenues Despite 26% Price Jump - Sahm
Biodesix stock soars as preliminary results exceed guidance, achieves EBITDA profitability - Investing.com Nigeria
Quarterly Trades: Will Biodesix Inc stock rally after Fed decisions2025 Market Overview & Growth Focused Entry Point Reports - Bộ Nội Vụ
Biodesix: Strengthening Fundamentals, Emerging Profitability, and Strategic Growth Support Buy Rating and $20 Price Target - TipRanks
Biodesix, Inc. at Risk: How a Federal Shutdown Could Disrupt Revenue and Growth - MSN
Biodesix: Strong Operational Momentum but Ongoing Capital Concerns Justify Hold Rating - TipRanks
Biodesix reports 41% revenue growth in Q4, exceeds 2025 guidance By Investing.com - Investing.com Nigeria
Biodesix sees stock soar after surpassing sales guidance - BizWest
BDSX Faces Financial Hurdles as Stock Volatility Heightens - StocksToTrade
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Biodesix Shares Rocket 42% on Record FY2025 Results and Path to Profitability - FinancialContent
BDSX Stock Shot Up 23% Pre-Market Today — What’s Fueling The Surge? - Asianet Newsable
Biodesix Stock Rebounds on Strategic Plans for Market Expansion - timothysykes.com
This Diagnostics Stock Is Surging 23% Pre-Market Today – Here’s Why - Stocktwits
Biodesix (BDSX) Surges 41% on Strong Preliminary Q4 and FY Resul - GuruFocus
Biodesix Surges On Strong Preliminary Q4 And FY2025 Revenue Results - Nasdaq
1.18%
자본화:
|
볼륨(24시간):